Biotechnology company Onxeo S.A. (CPH:ONXEO)(Paris:ONXEO) announced on Wednesday that the Ordinary Shareholders' General Meeting approved all the resolutions submitted to its vote, with over 88% of favourable votes.
Reportedly, in particular, the Ordinary General Meeting renewed the terms of office of Thomas Hofstaetter as director. Hofstaetter is chair of the Onxeo's compensation and business development committees.
According to the company, the quorum of 20.07% did not permit the resolutions to be discussed on an extraordinary basis.
As a result, the company's shareholders are invited to attend an
Extraordinary General Meeting on the second notice which will be held on 19 June 2018 at the company's headquarters in Paris, France, to deliberate on the same agenda.
Onxeo clarified that the votes of the shareholders who voted by mail for the first general meeting remain valid and counted for the general meeting on the second notice.
Onxeo develops oncology drugs based on DNA-targeting and epigenetics, two of the most sought-after mechanisms of action in cancer treatment currently.
Scancell initiates SCOPE trial's iSCIB1+ cohort
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates
BioVaxys Technology announces non-brokered private placement
Senhwa Biosciences doses first subject in phase II study of Silmitasertib
Antennova completes first dosing cohort in Phase one study of ATN-031
M8 Pharmaceuticals collaborates with SERB Pharmaceuticals
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib
Phanes Therapeutics receives FDA Fast Track designation for PT886